Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Operating Leases: 2021-2025

Historic Operating Leases for Prime Medicine (PRME) over the last 3 years, with Sep 2025 value amounting to $118.1 million.

  • Prime Medicine's Operating Leases rose 186.40% to $118.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $118.1 million, marking a year-over-year increase of 186.40%. This contributed to the annual value of $37.2 million for FY2024, which is 753.34% up from last year.
  • Latest data reveals that Prime Medicine reported Operating Leases of $118.1 million as of Q3 2025, which was down 1.34% from $119.7 million recorded in Q2 2025.
  • Prime Medicine's Operating Leases' 5-year high stood at $121.2 million during Q1 2025, with a 5-year trough of $3.1 million in Q4 2021.
  • Moreover, its 3-year median value for Operating Leases was $33.6 million (2024), whereas its average is $52.5 million.
  • Its Operating Leases has fluctuated over the past 5 years, first crashed by 74.45% in 2023, then surged by 753.34% in 2024.
  • Prime Medicine's Operating Leases (Quarterly) stood at $3.1 million in 2021, then skyrocketed by 455.41% to $17.1 million in 2022, then plummeted by 74.45% to $4.4 million in 2023, then skyrocketed by 753.34% to $37.2 million in 2024, then surged by 186.40% to $118.1 million in 2025.
  • Its last three reported values are $118.1 million in Q3 2025, $119.7 million for Q2 2025, and $121.2 million during Q1 2025.